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ABSTRACT
Red blood cell distribution width (RDW) is a quantitative measure of the 
variability in size of circulating erythrocytes. It was recently reported that RDW is a 
prognostic factor for infection diseases, cardiovascular and pulmonary diseases, as 
well as some neoplasms. Moreover, RDW is remarkably strong predictor of longevity, 
including all causes of death, for adults aged 45 years and older. To explain this 
occurrence it was proposed that persistent IGFs/mTOR signaling is one of the factors 
that play a role in affecting the RDW and mortality.
The above observations induced us to analyze the prognostic role of RDW in 
chronic lymphocytic leukemia (CLL) being the most frequent type of adult leukemia in 
Western countries. The obtained results have shown that RDW may be considered as a 
potential CLL prognostic marker. Elevated RDW level at the moment of diagnosis was 
associated with advanced disease and presence of other poor prognostic factors. It is 
also connected with overall survival indicating shorter time in patients with elevated 
RDW. It is possible that the presently observed correlation between mortality and 
RDW of the CLL patients is affected by their metabolic (IGF-1/mTOR driven)- rather 
than chronological- aging. The patients with high level of RDW are expected to have 
an increased persistent level of IGF-1/mTOR signaling. Within the framework of 
personalized therapy, these CLL patients therefore would be expected to be more 
sensitive to the treatment with mTOR inhibitors.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most 
frequently diagnosed leukemia of older patients in Western 
countries. The disease is characterized by the accumulation 
of leukemic CD19+/CD5+/CD23+ B cells in the blood, 
bone marrow, lymph nodes and spleen [1, 2, 3]. Lots of 
mechanisms involved in leukemic transformation are 
reported. The deletion of specific micro-RNA genes leads 
to the resistance of B lymphocytes towards apoptosis [1, 4]. 
The B cell receptor (BCR) signaling plays an important 
pathogenic role because of BCR-dependent survival of 
leukemic lymphocytes [5]. Additionally, the accessory cells 
of microenvironment can promote leukemic cell growth. 
BCR and chemokine receptors were reported to allow 
lymphocytes to be localized in lymphoid tissues and to form 
the CLL microenvironment [6].
Clinical course and prognosis of CLL are reported as 
extremely variable. Some persons with benign course never 
require therapy and die because of other than leukemic ones 
causes. In others the disease is aggressive and treatment 
is started soon after diagnosis. Many prognostic factors 
are used to predict clinical outcome of CLL patients. The 
clinically important ones are connected with the biology of 
the disease -the mutation status of the variable segment of 
immunoglobulin heavy chain genes (IgVH)), ZAP-70 and 
CD38 expression as indicators for IgVH mutations, as well 
as gene and genomic abnormalities [7, 8, 9, 10]. 
Red blood cell distribution width (RDW) is a 
quantitative expression of the size heterogeneity  of 
peripheral blood erythrocytes and is being usually 
automatically reported by laboratory blood analyzers in 
a complete blood cell count panels. RDW is presented 
as coefficient of variation (cv) of the mean value of 
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erythrocytes volume (Coulter volume). Recently, the role of 
RDW as a prognostic marker for infections, such as severe 
sepsis, pneumonia, infections caused by gram-negative 
bacteria and necrotizing fasciitis was described [11, 12, 
13, 14]. An elevated RDW unrelated of hemoglobin level, 
is connected with severe morbidity and mortality in the 
case of cardiovascular diseases, in kidney and pulmonary 
disorders [15, 16, 17, 18, 19]. RDW as a prognostic factor 
in hematological diseases was reported in patients with 
multiple myeloma [20]. Furthermore, RDW seems to be 
strong predictor of longevity, including all causes of death, 
with no apparent relationship to a particular disease, for 
people of age 45 and older [21].
The presented article aimed to analyze the possible 
role of RDW as a marker of prognosis in patients with CLL. 
Such a role of this parameter was expected because of the 
impairment of immunity in CLL patients and the fact that 
RDW is believed to reflect the general state of the patients 
and comorbidities related to their age, cardiovascular 
abnormalities or other infections.
RESULTS
Patients characteristics
A total number of 66 previously untreated persons 
with CLL diagnosis were analyzed. The median age was 63 
years, and 60% were males. Clinical characteristics of entire 
group of patients enrolled into the study is shown in Table 1. 
The median of pre-treatment RDW level was 13.5%, and the 
values ranged from 8.7 to 22.6%, while the normal ranges 
are established between 11.5% and 14.5%. The 14.5% cut-
off was used for analysis as first selection. Additionally, we 
performed the receiver operating characteristic (ROC) curve 
assessment of RDW for ZAP-70 positive/negative, CD38 
positive/negative, clinical classification early/advanced and 
cytogenetic risk standard/high, respectively, to find another 
significant cut-off points for RDW values. The estimated 
RDW cut-off point for ZAP-70 was 12.7%, for CD38–
13.7%, for clinical stadium was 14% and for cytogenetic risk 
groups–13.5%. However, the survival analysis has shown no 
significant differences in groups stratified according to these 
cut-offs. Thus, the selection of a 14.5% cut off for RDW 
positivity was chosen for final analysis. The analyzed subjects 
were classified as high-RDW (> 14.5%) and low-RDW 
(< 14.5). Table 2 presents clinical and laboratory parameters 
of persons stratified according to the RDW. High-RDW 
group included older persons comparing to low-RDW group, 
however the differences were not statistically significant. 
There were no statistically significant differences between 
the analyzed groups regarding white blood cell count and 
lymphocytosis, platelet count, lactate dehydrogenase level, 
β2-microglobulin level, presence of constitutive symptoms, 
lymphadenopathy or splenomegaly. Patients of high-RDW 
group were at more advanced stages when compared to 
low-RDW group (Figure 1). 
The patients were divided into two groups according 
to ZAP-70 and CD38 expression into positive group with 
ZAP-70 > 20% and CD38 > 20%, respectively and the 
negative group with ZAP-70 < 20% and CD38 < 20%, 
respectively. According to cytogenetic abnormalities the 
group of high-cytogenetic risk (del17p and del11q) and 
standard-cytogenetic risk group (trisomy of chromosome 12, 
del13q, no cytogenetic abnormalities) were distinguished. 
The RDW values were compared in the above groups. RDW 
was statistically significant higher in ZAP-70 positive and 
CD38 positive patients in comparison to ZAP-70 negative 
and CD38 negative subjects, respectively. In reference to 
cytogenetic changes, the difference were not statistically 
significant, however RDW was higher in high-cytogenetic 
risk group than in standard-cytogenetic risk one (Figure 2).
RDW assessment in regard to clinical outcomes
The clinical outcome data were analyzed in the 
group of patients who had to start the treatment (38 out of 
66 patients). The difference in time to treatment between 
low -RDW group and high-RDW group was observed, 
however it was not statistically significant. The median 
time to treatment in low-RDW group was not reached 
(58% probability to survive 5 years without therapy) and 
it was 2 months in high-RDW group (p > 0.05). There 
were no statistically significant differences in response 
to chemotherapy in the group of analyzed patients. The 
median overall survival time in low-RDW group was not 
reached (the probability to survive 5 years was 77%), while 
in high-RDW patients it was 52 months. This difference 
was at the border of statistical significance (p = 0.05). The 
Kaplan–Meier estimates of time to treatment and overall 
survival time are illustrated in Figure 3. In multivariate Cox 
proportional hazard regression analysis of RDW plus other 
prognostic factors: CD38 expression, ZAP-70 expression 
and group of cytogenetic risk (not simple cytogenetic 
abnormalities), the RDW level and ZAP-70 expression were 
found to be the independent predictors of shorter survival 
(p = 0.04 and p = 0.03, respectively).
In the group of treated patients we analyzed RDW 
values longitudinally in particular subjects in different 
points such as the moment of diagnosis, the disease 
progression and the end of chemotherapy. There was no 
significant differences in RDW as the disease progress. 
In most of cases RDW remained in the same group of 
stratification (low-RDW or high-RDW). Thus, RDW seems 
to be stable, not time-dependent prognostic marker. 
DISCUSSION
An elevated RDW has been found as a poor 
prognostic factor in several diseases. Specifically, it is 
associated with high rate of morbidity and mortality in 
the case of patients with chronic heart failure [22, 23, 24]. 
Likewise, it is a marker of poor prognosis for patients with 
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infectious diseases [25, 26]. However, there are relatively 
few reports focusing on RDW in the area of oncology. It is 
known that increase in RDW level indicates the presence 
of severe systemic inflammatory state that can worsen 
course of neoplastic diseases. RDW level can be influenced 
by anemia, which may worsen the course of neoplastic 
diseases as well. RDW appears to reflect the general 
condition of the patient, including such comorbidities as 
age, cardiovascular diseases and inflammation. It was 
reported that RDW was higher in women with aggressive 
breast cancer and is correlated with shorter survival in 
persons with lung cancer [27, 28, 29]. 
In the field of hematology the article by Lee et al. 
[20] focused on assessment of RDW in patients with 
symptomatic multiple myeloma. The observation that RDW 
level higher than normal at the moment of diagnosis was in 
correlation with more advanced disorder and poor prognosis 
prompted the authors to suggest that it could provide a 
novel and directly available predictor of severity of the 
disease. In fact, RDW may reflect both the inflammatory 
status as well as the patient’s global condition [20].
The above observations induced us to analyze the 
prognostic role of RDW in CLL. The obtained results 
have shown that indeed RDW may be considered a 
Table 1: Clinical characteristics of  analyzed CLL patients








































Table 2: Clinical parameters of analyzed CLL patients of Low-RDW (< 14.5%) and High-RDW 
(> 14.5%) groups
Low - RDW Group  High -RDW Group  p
Age (median) 59 63 NS
Lymphocytosis (109/L) 48 ± 43.5 75.7 + 60.3 NS
Hemoglobin (g%) 12.8 ± 1,7 11.4 ± 1.8 p < 0.05
Platelets (109/L) 157 ± 75,2 140 ± 70.6 NS
LDH  (IU/L) 370 ± 126 408 ± 145 NS
β2-microglobulin (mg/dl) 2.34 ± 0.7 5.44 ± 2.7 NS
Statistical significance is indicated (p values); NS – not significant.
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Figure 1: Clinical stadium according to Rai classification [30] of the analyzed CLL patients in High-RDW group 
(RDW > 14.5 %) and Low-RDW group (RDW < 14.5%).
Figure 2: RDW values in CLL risk groups. RDW values in ZAP-70 negative (ZAP-70-) and ZAP-70 positive (ZAP–70+) CLL 
patients (A). RDW values of CLL patients in CD38 negative (CD38−) and CD38 positive (CD38+) group (B). RDW values of analyzed 
patients in the standard-risk cytogenetic group (del13q14.3, trisomy 12, or no changes detected) and in the high-risk cytogenetic group 
(17p13.1 or 11q22.3) (C). All graphs show mean ± standard deviation. NS not statistically significant.
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prospective prognostic biomarker in this disease. The 
present data demonstrate that RDW is in correlation with 
other prognostic factors such as clinical stadium of the 
disease, expression of ZAP-70 and CD38. Anemia can 
be a symptom of CLL showing the most advanced stage 
of disease. In the presented study we have pointed that 
hemoglobin level is in correlation with RDW, but other 
CLL parameters such as ZAP-70 and CD38 expression 
have also changed according to RDW stratification It 
should be noted that anemia in neoplastic diseases like 
CLL does not simply reflect a decrease in peripheral 
blood erythrocytes number but may be a parameter of 
inflammation status as well, being associated with impaired 
iron release from reticuloendothelial macrophages [20].
Clinical stadium of the disease for many years belongs 
to the most important prognostic factors in CLL. Nowadays, 
two staging methods - the Rai [30] and the Binet system 
[31] co-exist and are widely used in clinical practice. Early 
stage 0 disease according to Rai classification describes 
patients with lymphocytosis detected in the peripheral 
blood and bone marrow. Patients with lymphocytosis and 
enlarged lymph nodes are classified at stadium I and those 
with splenomegaly at stadium II. High risk disease includes 
patients with leukemia-related anemia or thrombocytopenia 
(stage III and IV, respectively) [30, 32]. The Binet staging 
system is based on the number of involved areas of lymph 
nodes or organomegaly and on whether there is anemia 
or thrombocytopenia [31, 32]. In general practice, newly 
diagnosed patients with asymptomatic early-stage disease 
should be observed without treatment. The patients at 
intermediate and high risk usually have to start treatment, 
however some of them can be observed without therapy 
until disease progression [22, 32]. Among the biological 
CLL prognostic markers the IgVH mutation status or its 
Figure 3: Time to treatment (A) and total survival time (B) demonstrated by Kaplan-Meier curves. The patients were 
stratified according to RDW level (Low-RDW group versus High-RDW group). Statistical significance is indicated. 
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surrogate markers (ZAP-70 and CD38 expression) as well 
as genomic aberrations may identify the subjects with 
more aggressive leukemia and poor prognosis [7, 33]. The 
correlations between RDW level and some prognostic 
markers of CLL detected in our analysis may indicate the 
role of RDW assessment in prognosis of CLL patients.
Further analysis performed in our study was focused 
on association between RDW level and clinical outcomes. 
We detected no differences between the time of the initiating 
of the therapy as far as RDW level was concerned, however 
the differences in overall survival time were significant. As 
mentioned, strong association between RDW and longevity 
has been shown for subjects 45 years and older [21]. This 
association remains strong after discounting all types of red 
blood cell diseases [21]. To explain this occurrence it was 
proposed that persistent signaling along the IGFs/mTOR 
pathway is one of the key factors that play a role in affecting 
the RDW and mortality [34–36]. Specifically, there are the 
data that IGF-1/mTOR signaling enhances erythropoiesis 
by activation of erythropoietin [36, 37] and affects the final 
steps of erythroid lineage maturation [38]. The IGFs/mTOR 
also strikingly influences the cell size as shown for 32D- 
originated myeloid cells that are 50% smaller while having 
deleted IGF-1 receptor [39]. It may be possible therefore 
that persistent activation of erythropoiesis through IGF-1/
mTOR results in heterogeneity of red cell sizes due to their 
higher turnover rates. On the other hand the elevated level 
of GH/IF-1/mTOR signaling is considered to be the primary 
cause of aging and age-associated mortality [39, 40]. Given 
the above it may be expected that RDW may be a useful 
marker of the constitutive level of IGF-1 signaling, the 
critical factor accountable for metabolic aging and longevity 
[21]. It is possible, therefore, that the presently observed 
correlation between mortality and RDW of the CLL patients 
is affected by their metabolically driven (growth factor - 
IGF-1/mTOR)- rather than chronological- aging. 
Attempts have been recently made to apply mTOR 
inhibitors in treatment of leukemia, including CLL [41, 
42, 43]. Along the rationale presented above the patients 
with high level of RDW are expected to have an increased 
persistent level of IGF-1/mTOR signaling. Within the 
framework of personalized therapy, these CLL patients 
therefore would be expected to be more sensitive to the 
treatment with mTOR inhibitors. 
In conclusion, the presented study underscores 
the potential role of RDW as a prognostic factor in CLL. 
Elevated RDW level at diagnosis was associated with 
advanced disease and the presence of other poor prognostic 
factors. It was also connected with life expectancy 
indicating shorter survival time of patients with elevated 
RDW. These results thus indicate that RDW may be 
considered as a simple and easily available prognostic 
factor. Such a role of RDW could be anticipated considering 
that RDW may reflect the overall conditions of the patients 
and be associated with their longevity (21). Further studies, 
however are required to ascertain specifically molecular 
mechanism(s) linking the increased RDW with poor 
prognosis of CLL. 
MATERIALS AND METHODS
Patients
We performed a retrospective analysis of the medical 
records of a group of patients diagnosed with CLL in our 
Department. Diagnosis of the disease was made on the basis 
of clinical examination, morphological and immunological 
criteria. The persons who had complete blood count tests 
results available with the reported RDW before treatment 
were enrolled into the study; those who had received a 
blood transfusion within the previous six months were 
excluded. Finally sixty six patients were analyzed. We used 
a coding system to assure the anonymity of the patients 
enrolled into the study.
Measurement of RDW
RDW was measured with use of automatic analyzer 
Sysmex XS-1000i and was reported as a coefficient of 
variation of the mean red blood cell volume. The reference 
range for RDW was 11.5% to 14.5%. 
Data collection
Firstly, the age, sex and data of CLL diagnosis were 
recorded. The laboratory findings beside RDW collected 
at the moment of diagnosis including white blood cell 
count and lymphocyte count, hemoglobin level, platelet 
count, lactate dehydrogenase level, β2microglobulin level, 
presence of constitutive symptoms, lymphadenopathy or 
splenomegaly were then reviewed. All patients were also 
characterized according to expression of ZAP-70 and 
CD 38 that were assessed with flow cytometry method 
and according to presence of cytogenetic abnormalities 
assessing with FISH (fluorescence in situ hybridization) 
method. The next step of analysis was focused on therapy 
data. We analyzed time from diagnosis to starting of the 
therapy, chemotherapy regimens ordered and chemotherapy 
outcome. We used the criteria of response to treatment 
proposed by WG- IWCLL in 2008 [44] based on WG- 
NCI criteria from1996 [45]. According to these criteria, 
complete response requires the absence of symptoms and 
organomegaly, normal complete cell counts of peripheral 
blood and less than 30% of lymphocytes in bone marrow 
for at least 2 months. When size of the lymph nodes, spleen 
and liver, together with the peripheral blood data, were 
at least 50% better than pre-treatment values, the partial 
response was achieved. Other patients were considered 




The collected data were analyzed using STASTICA 12 
Software by StatSoft Inc. The Mann-Whitney and Wilcoxon 
tests were used for groups comparison. The Kaplan–Meier 
method was employed to calculate the survival analysis. 
Multivariate analysis of independent clinical factors 
for survival was tested by the Cox proportional hazard 
regression model. The assessment of cut-off points for 
RDW were assessed by drawing of receiver operating 
characteristic (ROC) curves using Medical Bundle for 
STATISTICA 12. Differences were considered statistically 
significant when p values were < 0.05.
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